Xencor Inc (XNCR) - Total Assets
Based on the latest financial reports, Xencor Inc (XNCR) holds total assets worth $868.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xencor Inc - Total Assets Trend (2011–2024)
This chart illustrates how Xencor Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of Xencor Inc for the company's overall valuation and market capitalisation.
Xencor Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Xencor Inc's total assets of $868.81 Million consist of 60.7% current assets and 39.3% non-current assets. Review how much debt does Xencor Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.3% |
| Accounts Receivable | $60.85 Million | 6.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.48 Million | 1.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Xencor Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Xencor Inc (XNCR) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xencor Inc's current assets represent 60.7% of total assets in 2024, a decrease from 65.5% in 2011.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2024, down from 65.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 32.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
Xencor Inc Competitors by Total Assets
Key competitors of Xencor Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Xencor Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.99 | 6.23 | 5.27 |
| Quick Ratio | 5.99 | 6.23 | 5.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $431.96 Million | $481.36 Million | $516.61 Million |
Xencor Inc - Advanced Valuation Insights
This section examines the relationship between Xencor Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | $951.95 Million |
| Market Capitalization | $827.65 Million USD |
Valuation Analysis
Near Book Valuation: The market values Xencor Inc's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Xencor Inc's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xencor Inc (2011–2024)
The table below shows the annual total assets of Xencor Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $951.95 Million | -0.08% |
| 2023-12-31 | $952.69 Million | +12.58% |
| 2022-12-31 | $846.27 Million | +0.96% |
| 2021-12-31 | $838.21 Million | +19.19% |
| 2020-12-31 | $703.24 Million | +4.92% |
| 2019-12-31 | $670.25 Million | +16.22% |
| 2018-12-31 | $576.73 Million | +47.84% |
| 2017-12-31 | $390.10 Million | -8.97% |
| 2016-12-31 | $428.56 Million | +107.13% |
| 2015-12-31 | $206.91 Million | +205.07% |
| 2014-12-31 | $67.82 Million | -22.32% |
| 2013-12-31 | $87.31 Million | +648.91% |
| 2012-12-31 | $11.66 Million | -47.89% |
| 2011-12-31 | $22.37 Million | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more